Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

NCT02580591 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

977

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: Empagliflozin
DRUG: Placebo

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]